GlycoMimetics updates IPO

IPO plans for inflammation and infectious play GlycoMimetics Inc. (Gaithersburg, Md.) seem to be on track after the company filed an S-1A filing on Friday. Jefferies; Barclays; Stifel; and Canaccord Genuity are underwriters. In early November, GlycoMimetics was rumored to have postponed its IPO; the company declined to comment on the rumors. Since then, there has been no other SEC activity for GlycoMimetics until Friday's filing.

Friday's filing no longer has details on the offering, including a share price range or proposed number of shares. In late October, GlycoMimetics had said it planned to sell 4 million shares at $14-$16. At the $15 midpoint, the company would raise $85 million and be valued at $413.9 million. GlycoMimetics first filed to raise up to $86.3 million in the IPO in early October (see BioCentury, Nov. 18). ...